Biosyent Inc
XTSX:RX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biosyent Inc
XTSX:RX
|
CA |
|
Tata Power Company Ltd
NSE:TATAPOWER
|
IN |
|
Catella AB
STO:CAT B
|
SE |
|
C
|
Carrefour SA
F:CAR
|
FR |
|
Ascentech KK
TSE:3565
|
JP |
|
D
|
Dimeco Inc
OTC:DIMC
|
US |
|
P
|
PCCS Group Bhd
KLSE:PCCS
|
MY |
|
N
|
Nakayamafuku Co Ltd
TSE:7442
|
JP |
|
Comsys Holdings Corp
TSE:1721
|
JP |
|
Nexteer Automotive Group Ltd
HKEX:1316
|
US |
|
E
|
Exsitec Holding AB
STO:EXS
|
SE |
|
Artisanal Spirits Company PLC
LSE:ART
|
UK |
|
3M India Ltd
NSE:3MINDIA
|
IN |
|
N
|
Nippon Seiro Co Ltd
TSE:5010
|
JP |
|
Z
|
Zhejiang Zhongke Magnetic Industry Co Ltd
SZSE:301141
|
CN |
|
G
|
General Commercial and Industrial SA
ATHEX:GEBKA
|
GR |
|
Kingston Financial Group Ltd
HKEX:1031
|
HK |
|
Dah Sing Banking Group Ltd
HKEX:2356
|
HK |
Biosyent Inc
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.
Results: Q4 revenue was just under $9.7 million (up 10% YoY); full-year revenue exceeded $43 million (up 23% YoY).
Profitability: Q4 EBITDA was just over $2.5 million and NIAT just under $2 million; full-year EBITDA just over $12.1 million and NIAT just over $9 million, with EPS $0.78 for the year ($0.17 in Q4).
Acquisition: Closed acquisition of Oral Science on March 1 for $25.5 million (plus $2 million excess working capital); Oral Science had just under $31 million revenue and $4.1 million EBITDA in 2025.
Financing: Acquisition funded with $16.3 million cash on hand, $8 million bank debt (term $6M + $2M revolver), $3 million in shares and $200,000 RSUs; company reported ~$17 million cash the day after closing and expects to repay bank debt in 2026.
Capital returns: Quarterly dividend increased (now $0.05/quarter), $0.20 paid in 2025 and expected $0.22 for the coming year; NCIB and buybacks will resume opportunistically.
Outlook/strategy: Oral Science broadens BioSyent into oral health, creates a second platform for in‑licensing and acquisitions and makes the business more diversified and cash-generative on a pro forma >$70M revenue basis.
